Avanza Fonder AB Has $4.45 Million Stake in IDEXX Laboratories, Inc. $IDXX

Avanza Fonder AB grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,574 shares of the company’s stock after purchasing an additional 1,078 shares during the period. Avanza Fonder AB’s holdings in IDEXX Laboratories were worth $4,448,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of IDXX. Congress Asset Management Co. lifted its stake in IDEXX Laboratories by 9,894.0% in the 4th quarter. Congress Asset Management Co. now owns 153,908 shares of the company’s stock valued at $104,123,000 after acquiring an additional 152,368 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in IDEXX Laboratories by 35.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 75,609 shares of the company’s stock worth $51,152,000 after acquiring an additional 19,741 shares during the last quarter. Park Place Capital Corp bought a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $29,000. Diversified Trust Co. grew its stake in shares of IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after acquiring an additional 2,901 shares in the last quarter. Finally, Norway Savings Bank raised its holdings in shares of IDEXX Laboratories by 25.5% in the fourth quarter. Norway Savings Bank now owns 4,631 shares of the company’s stock valued at $3,133,000 after purchasing an additional 941 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $570.21 on Wednesday. The stock has a market capitalization of $45.34 billion, a PE ratio of 43.63, a P/E/G ratio of 3.51 and a beta of 1.66. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The firm has a fifty day simple moving average of $639.93 and a 200 day simple moving average of $663.76. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business earned $2.53 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 45,957 shares of company stock worth $29,862,109 in the last 90 days. 0.98% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on IDXX shares. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. BTIG Research reduced their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. UBS Group decreased their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Finally, Barclays lowered their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.